Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival

ConclusionIn this series of RAI-R DTC patients, with the unique features to have an ECOG 0 or 1 and to be naive for TKI treatments, PFS was the longest among all real-life published so far, with the highest rate of patients with partial response and one of the lowest drug discontinuation rate for AEs. The correct timing of treatment start, the tailoring of the dose, and a proper management of the AEs may have a significant impact on the treatment response to LEN.
Source: Endocrine - Category: Endocrinology Source Type: research